Old Web
English
Sign In
Acemap
>
authorDetail
>
Chetan Rathi
Chetan Rathi
GlaxoSmithKline
Medicine
Oncology
Internal medicine
Cancer research
Multiple myeloma
4
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
2021
Clinical Pharmacology & Therapeutics
Geraldine Ferron-Brady
Chetan Rathi
Jon L. Collins
Herbert Struemper
Joanna Opalinska
Sandra A.G. Visser
Roxanne C. Jewell
Show All
Source
Cite
Save
Citations (1)
Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma.
2021
Chetan Rathi
Jon L. Collins
Herbert Struemper
Joanna Opalinska
Roxanne C. Jewell
Geraldine Ferron-Brady
Show All
Source
Cite
Save
Citations (2)
Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
2020
Blood
Geraldine Ferron-Brady
Chetan Rathi
Jon L. Collins
Herbert Struemper
Joanna Opalinska
Roxanne C. Jewell
Show All
Source
Cite
Save
Citations (2)
A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors.
2019
Journal of Clinical Oncology
Deirdre Jill Cohen
Shubham Pant
Bert H. O’Neil
Jill M. Marinis
James Winnberg
Christoph Matthias Ahlers
Justin Callaway
Chetan Rathi
Andre P. Acusta
Adeline Verticelli
John Bertin
James F. Smothers
Show All
Source
Cite
Save
Citations (0)
1
map